Shares of CorMedix Inc (NASDAQ:CRMD – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight ratings firms that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $15.00.
A number of research analysts have recently issued reports on CRMD shares. Zacks Research raised CorMedix from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Weiss Ratings raised CorMedix from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, May 14th. Needham & Company LLC upped their price target on CorMedix from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, April 27th. Leerink Partners upped their price objective on CorMedix from $13.00 to $14.00 and gave the company an “outperform” rating in a research report on Tuesday, April 28th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $14.00 target price (up from $13.00) on shares of CorMedix in a report on Tuesday, April 28th.
Get Our Latest Stock Report on CorMedix
Hedge Funds Weigh In On CorMedix
CorMedix Price Performance
CRMD opened at $7.64 on Thursday. CorMedix has a 12-month low of $6.13 and a 12-month high of $14.96. The company has a market cap of $599.36 million, a price-to-earnings ratio of 3.59 and a beta of 1.46. The stock has a fifty day simple moving average of $8.08 and a two-hundred day simple moving average of $8.15. The company has a current ratio of 2.97, a quick ratio of 2.74 and a debt-to-equity ratio of 0.33.
CorMedix (NASDAQ:CRMD – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.35 by $0.08. The firm had revenue of $127.43 million for the quarter, compared to analysts’ expectations of $104.96 million. CorMedix had a return on equity of 45.57% and a net margin of 45.25%.The company’s quarterly revenue was up 226.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.30 earnings per share. Research analysts predict that CorMedix will post 0.51 earnings per share for the current fiscal year.
CorMedix Company Profile
CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.
In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.
Featured Stories
- Five stocks we like better than CorMedix
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.
